Tag Archives: Ingelheim

Boehringer Ingelheim’s New €285m Chemical Plant to Boost Pharmaceutical Innovation

(IN BRIEF) Boehringer Ingelheim has begun construction on a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. The €285 million investment will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for clinical trial phases, enabling Boehringer … Read the full press release

Boehringer Ingelheim partners with Taizhou China Medical City to open leading veterinary manufacturing plant in Jiangsu Province, China

Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu, China, and Ingelheim, Germany, 27-8-2013 — /EuropaWire/ — Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical … Read the full press release

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release

Boehringer Ingelheim and Eli Lilly presented clinical trials results evaluating linagliptin efficacy and safety in Asians with Type 2 Diabetes

2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release

Boehringer Ingelheim, Lilly released results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at the American Diabetes Association

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release